Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2026-04-24 @ 4:42 AM
Study NCT ID:
NCT01613118
Status:
COMPLETED
Last Update Posted:
2025-05-15
First Post:
2012-06-04
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Sponsor:
Travere Therapeutics, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
RET-D-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None